A Closer Look at Emerging Therapies in
the Management of Alopecia Areata: Managed Care Considerations on
JAK Inhibitors in an Evolving Treatment Landscape
A continuing medical education
activity provided by NAMCP and AAMCN
Preparing for a New Era in Alopecia Areata Management: Managed Care
on the Role of New and Emerging Therapies is a three-part webinar
This is Part 1 of the series focusing on management of Alopecia
This activity is an archive from the webinar held March 24, 2021
This activity is valid from April 1, 2021 to April 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from Pfizer
Alopecia areata is an autoimmune disease, characterized by hair
loss, often patchy, on the scalp, face, or body. People suffering
from alopecia areata experience symptoms when immune cells attack
healthy hair follicles, causing the hair to fall out, often starting
with smooth, round patches. More than half of patients with alopecia
areata experience poor health-related quality of life and, as a
result, the condition may lead to serious psychological
consequences, including high levels of depression and anxiety.
Fortunately for patients with this disease, several new treatments
are currently undergoing late stage clinical trials, including JAK
inhibitors and combinations, that have shown improved efficacy and
Upon completion of this
activity, participants will be able to:
Examine the unmet clinical needs in
alopecia areata and the impact of inadequately treated disease
on physical and mental health, quality of life, costs and work
Assess recent pathophysiological
findings in alopecia areata that have informed the study of new
therapeutic targets, including JAK inhibitors
Analyze new evidence pertaining to
the safety and efficacy of new and emerging therapies in the
management of alopecia areata
Explore the role of emerging JAK
inhibitors in the management of alopecia areata for patients in
all age groups
||Brett King, MD, PhD
Associate Professor of Dermatology
Yale University School of Medicine
MD, PhD has disclosed the following financial
relationships during the past 24 months with any entity
whose primary business is producing, marketing, selling,
re-selling, or distributing healthcare products used by
or on patients: Dr. King has served as a consultant for
Aclairis Therapeutics Inc, Almirall, Arena
Pharmaceuticals, Bristol Myers Squibb, Concert
Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly
and Company, Incyte Corp, Prizer Inc, TWi Biotechnology
Inc, Viela Bio. Dr. King as spoken for Pfizer Inc,
Regeneron, and Sanofi Genzyme. This presentation has
been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue